Thill M and Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 2018; 10: 1-12. DOI: 10.1177/1758835918793326
In the article ‘Management of adverse events during CDK 4/6 inhibitor-based treatment in breast cancer’, the data in the ‘Results’ column for the MONALEESA-7 trial were incorrect (5th row of the table). The data should have read ‘23.8 versus 13.0 months PFS’ instead of ‘13.8 versus 13.8 months (hazard ratio 0.55)’.
This has been corrected in the PDF and HTML versions of the article.